Glenmede Trust’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Glenmede Trust’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-230	Closed	-$13K	–	2654
2015 Q3	$13K	Buy	+230	New	+$19.6K	﹤0.01%	2033
2015 Q1	–	Sell	-1,100	Closed	-$69K	–	2449
2014 Q4	$69K	Buy	+1,100	New	+$64.5K	﹤0.01%	1658
2014 Q3	–	Sell	-2,400	Closed	-$111K	–	2458
2014 Q2	$111K	Buy	2,400 +100	+4%	+$3.95K	﹤0.01%	1365
2014 Q1	$91K	Sell	2,300 -1,980	-46%	-$89.9K	﹤0.01%	1453
2013 Q4	$161K	Buy	4,280 +480	+13%	+$16K	﹤0.01%	1227
2013 Q3	$123K	Buy	3,800 +800	+27%	+$23.2K	﹤0.01%	1299
2013 Q2	$67K	Buy	+3,000	New	+$68.5K	﹤0.01%	1439

Other funds holding BIB

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

RIA

RPG Investment Advisory Pleasanton, California $829M AUM 36.68% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VCAM

Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Glenmede Trust's BIB Position: Q4 2015 in Review

Glenmede Trust sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2015, closing a stake of 230 shares — an estimated $13K sold.

Glenmede Trust first reported a position in BIB in Q2 2013 and held it in 7 quarters. The position peaked at $161K in Q4 2013. 27 funds tracked by Wall St. Rank hold BIB as of Q4 2015.

Glenmede Trust reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2015 after selling out during the quarter.
Glenmede Trust sold 230 ProShares Ultra NASDAQ Biotechnology shares in Q4 2015, an estimated $13K.
Glenmede Trust first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2013 and held it in 7 quarters.
Glenmede Trust's ProShares Ultra NASDAQ Biotechnology position peaked at $161K in Q4 2013.
27 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2015.

Based on Glenmede Trust's 13F filing for Q4 2015, filed 11 Feb 2016.